



Short Note (E)-4-(3-Phenylisoxazol-5-yl)but-3-en-2-one

Nattawut Sawengngen¹, Alexandra A. Kolodina² and Olga V. Serdyuk^{1,*}

- ¹ Department of Chemistry and Pharmacy, Institute of Organic Chemistry I, University of Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; sawengngen.n@gmail.com
- ² Institute of Physical and Organic Chemistry, Southern Federal University, 194/2 Stachki St., Rostov on Don 344090, Russia; akolodina@sfedu.ru
- * Correspondence: olga@serdyuk.de; Tel.: +49-9131-85-65345

Received: 19 August 2019; Accepted: 17 September 2019; Published: 18 September 2019




Abstract: (*E*)-4-(3-Phenylisoxazol-5-yl)but-3-en-2-one was synthesized via the oxidative ring opening reaction of 2-(5-methylfuran-2-yl)-1-phenylethanone oxime, followed by the iodine mediated isomerization.

Keywords: oxazole; furan; RORC reaction; (*E*,*Z*)-isomerization

1. Introduction

The isoxazole ring is a structural motif of numerous bioactive compounds, including several marketed drugs [1]. Substituted isoxazoles are known as promising anticancer [2–5], antifungal [6], antidepressant [7], antioxidant [8], and antituberculous agents [9]. Additionally, some of the isoxazoles demonstrate herbicidal [10] and insecticidal [11] properties.

In 2017, Pinho e Melo et al. described a new synthesis of isoxazoles from tetrahydrofurooxazines via the intermediate formation of oximes (Scheme 1) [12]. Main products of this acid-catalyzed reaction were substituted 4-(isoxazol-5-yl)butan-2-ones **3**. On the other hand, minor isoxazolylvinyl ketones (*E*)-**4** are of special interest, due to an active enone fragment, which can be utilized for the construction of linked isoxazoles [13] and other new complex structures containing an isoxazole subunit [14].




Scheme 1. Acid-catalyzed formation of isoxazolylvinyl ketones as minor products.

Herein, we describe an easy approach to (*E*)-4-(3-phenylisoxazol-5-yl)but-3-en-2-one **4c**, and its characterization by 1D and 2D NMR spectroscopy.


2. Results and Discussion

Oxime **2c** was synthesized via the reaction of furfuryl ketone **5** with hydroxylamine hydrochloride, and sodium acetate in ethanol. The subsequent furan ring opening–isoxazole ring closure reaction of **2c** under oxidative conditions [15,16] provided the target 4-(3-phenylisoxazol-5-yl)but-3-en-2-one **4c** in high yield as a mixture of (E,Z)-isomers (Scheme 2).



Scheme 2. Synthesis of compound 4c.

Isoxazole (*E*)-**4c** was obtained in a pure form through iodine-mediated isomerization [17] and fully characterized (Scheme 3).




Scheme 3. Isomerization (E,Z)-4c \rightarrow (*E*)-4c.

The structure of compound **4c** was confirmed by 1H and 2D nuclear magnetic resonance spectroscopy: ¹H-¹H correlation spectroscopy (COSY), ¹H-¹³C heteronuclear single-quantum correlation spectroscopy (HSQC), and ¹H-¹³C heteronuclear multiple-bond correlation spectroscopy (HMBC) (Figures 1–3). In the ¹H NMR spectrum of (*E*)-**4c**, signals of the vinyl protons α -H and β -H are observed at δ H = 6.95 and 7.40 ppm, respectively, and have a coupling constant of 16.2 Hz, which indicates a (*E*)-configuration (Figure S1). In the ¹H-¹³C HMBC spectrum, there are cross-peaks between the α -H proton and C-atom of the methyl group (δ C 28.5 ppm) and isoxazole C(5) atom (δ C 166.3 ppm). The β -H proton correlates with carbonyl carbon atom at δ C 197.0 ppm and isoxazole C(4) atom at δ C 104.5 ppm. Cross-peaks between the proton H(4) at δ H 6.80 ppm and β -C atom of the acetyl vinyl fragment at δ C 130.8 ppm are observed as well. All key cross-peaks are presented in Table 1.

Table 1. Cross-peaks in heteronuclear single-quantum correlation and heteronuclear multiple-bond correlation spectra of compound (*E*)-**4c**.

130.8

197.0



In summary, we have suggested an effective route to (E)-4-(3-phenylisoxazol-5-yl)but-3-en-2-one employing oxidative RORC reaction of furfuryl ketone oxime. The exploration of the reaction scope is underway in our laboratory.




Figure 1. Data of ¹H-¹H correlation spectroscopy for compound (*E*)-4c (CDCl₃).




Figure 2. Data of 1 H- 13 C heteronuclear multiple-bond correlation spectroscopy for compound (*E*)-4c (CDCl₃).




Figure 3. Data of ${}^{1}\text{H}{}^{-13}\text{C}$ heteronuclear single-quantum correlation spectroscopy for compound (*E*)-4c (CDCl₃).

3. Materials and Methods

All commercial products and solvents were used without further purification (Fisher Scientific, Loughborough, UK). All reactions were run under the air unless noted otherwise.

The reactions under microwave irradiation were conducted in Microwave Synthesis Reactor «Biotage[®] Robot Eight» (Biotage AB, Uppsala, Sweden) using sealed microwave reaction vessels. TLC analyses were performed on Merck 60 F254 aluminum plates in combination with UV detection (254 nm). Flash chromatography was performed on silica gel 200–300 mesh (Merck, Darmstadt, Germany) using mixture EtOAc/*i*-hexane as eluents. Melting points were determined on a Mel-Temp II Laboratory Devices apparatus (Triad Scientific Manasquan, Manasquan, NJ, USA); the values are uncorrected. NMR spectra were recorded on a Bruker AV-600 (¹H NMR at 600 MHz and ¹³C NMR at 151 MHz,) and Bruker AV-400 (¹H NMR at 400 MHz and ¹³C NMR at 101 MHz) spectrometers (Bruker GmbH, Mannheim, Germany). Proton chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS), with the solvent resonance employed as the internal standard (CDCl₃ δ = 7.26 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets), coupling constants (*J*) and integration. Coupling constants (*J*) are reported in Hertz (Hz). Carbon chemical shifts are reported in ppm from tetramethylsilane (TMS), with the solvent resonance as the internal standard (CDCl₃ δ = 77.16 ppm).

IR spectra were measured on PerkinElmer Spectrum BX spectrophotometer (NaCl plates, PerkinElmer LAS GmbH, Rodgau, Germany). HRMS-ESI spectra were recorded at The Mass Spectroscopy Laboratory, Chair of Organic Chemistry, Friedrich-Alexander University of Erlangen-Nuremberg.

Starting furfuryl ketone 5 was obtained according to the published procedure [18].

2-(5-Methylfuran-2-yl)-1-phenylethan-1-one oxime (2c)

Hydroxylamine hydrochloride (2 mmol) and anhydrous NaOAc (4 mmol) were added to a solution of furfuryl ketone 5 (2 mmol) in ethanol (5 mL), and the mixture was stirred for 24 h at 80 °C (TLC and LC-MS control). Then, the reaction mixture was poured into H_2O (100 mL) and extracted with EtOAc (4 × 25 mL). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The resulting crude product was purified by flash chromatography using EtOAc/*i*-Hex as eluents.

Yield 0.61 g (100%). White solid. M.p. 90–92 °C. ¹H NMR (600 MHz, CDCl₃): δ = 7.69–7.67 (m, 2H), 7.37–7.36 (m, 3H), 5.92 (d, *J* = 3.0 Hz, 1H), 5.83 (m, 1H), 4.13 (s, 2H), 2.24 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 155.2, 150.9, 147.9, 135.3, 129.4, 128.5, 126.4, 107.5, 106.3, 25.5, 13.6 ppm. IR (NaCl): 3241, 2922, 1568, 1495, 1461, 1321, 1168, 1016, 960 cm⁻¹. HRMS (ESI): *m/z* calcd. for C₁₃H₁₃NO₂ [M-H]⁺: 214.0868; found: 214.0862.

(E,Z)-4-(3-Phenylisoxazol-5-yl)but-3-en-2-one ((E,Z)-4c)

m-CPBA (77% w/w, 0.135 g, 0.6 mmol) was added to a solution of oxime **2c** (0.5 mmol) in DCM (2 mL) at 0 °C. The reaction mixture was stirred at the same temperature for 1 h. Then TFA (0.038 mL, 0.05 mmol) was added. The reaction mixture was allowed to reach room temperature and stirred for 20 h. Once the reaction was complete, the mixture was washed with Na₂S₂O₃ solution three times, and then with brine. DCM was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure to give a pure (*E*,*Z*)-4.

(Z)-4-(3-Phenylisoxazol-5-yl)but-3-en-2-one ((Z)-4c)

In a mixture with (*E*)-isomer. ¹H NMR (600 MHz, CDCl₃): δ = 7.87–7.86 (m, 2H), 7.69 (s, 1H), 7.48–7.44 (m, 3H), 6.74 (d, *J* = 12.8 Hz, 1H), 6.43 (d, *J* = 12.8 Hz, 1H), 2.37 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 197.8, 166.0, 163.2, 130.8, 130.4, 130.1, 128.9, 126.8, 123.5, 106.0, 31.5 ppm.

Isomerization (E,Z)-**4** \rightarrow (E)-**4**

Microwave reaction vessel was charged with (*E*,*Z*)-**4c** (0.2 mmol), I_2 (0.0034 g, 0.013 mmol), and toluene (5 mL). The reaction mixture was stirred at 140 °C in a microwave reactor for 2 h. After completion of the reaction, toluene and iodine were removed under reduced pressure to afford pure (*E*)-**3a**.

(E)-4-(3-Phenylisoxazol-5-yl)but-3-en-2-one) (E)-4c)

Yield 0.034 g (80%). White solid. M.p. 130–132 °C. ¹H NMR (600 MHz, CDCl₃): δ = 7.83–7.81 (m, 2H), 7.49–7.47 (m, 3H), 7.40 (d, *J* = 16.2 Hz, 1H), 6.95 (d, *J* = 16.2 Hz, 1H), 6.80 (s, 1H), 2.41 (s, 3H) ppm. ¹³C NMR (151 MHz, CDCl₃): δ = 197.0, 166.3, 163.1, 130.8, 130.4, 129.1, 128.4, 126.8, 125.4, 104.5, 28.5 ppm. IR (NaCl): 1664 (C=O), 1560, 1439, 1268, 983, 952, 769 cm⁻¹. HRMS (ESI): *m/z* calcd. for C₁₃H₁₁NO₂ [M + H]⁺: 214.0868; found: 214.0861.

Supplementary Materials: The following are available online, Figure S1: ¹H NMR spectrum of compound **2c**, Figure S2: ¹³C NMR spectrum of compound **(***E***)-4c**, Figure S4: ¹³C NMR spectrum of compound (*E***)-4c**, Figure S5: ¹H NMR spectrum of compound (*Z***)-4c**, Figure S6: ¹³C NMR spectrum of the compound (*Z***)-4c**.

Author Contributions: N.S.—synthesis, A.A.K.—NMR data analysis, writing the manuscript, O.V.S.—conceptualization, supervision, data analysis, writing the manuscript, funding acquisition. All authors read and approved the final manuscript.

Funding: This research was funded by the program "Promotion of Equal Opportunities for Women in Research and Teaching" (FFL) Bayern, Germany.

Acknowledgments: We thank Peter Gmeiner, Department of Chemistry and Pharmacy, University of Erlangen-Nuremberg, for his kind support.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Sysak, A.; Obmińska-Mrukowicz, B. Isoxazole ring as a useful scaffold in a search for new therapeutic agents. *Eur. J. Med. Chem.* **2017**, *137*, 292–309. [CrossRef] [PubMed]
- 2. Rajanarendar, E.; Nagi Reddy, M.; Rama Krishna, S.; Govardhan Reddy, K.; Reddy, Y.N.; Rajam, M.V. Design, synthesis, in vitro antimicrobial and anticancer activity of novel methylenebis-isoxazolo [4,5-*b*]azepines derivatives. *Eur. J. Med. Chem.* **2012**, *50*, 344–349. [CrossRef] [PubMed]
- Güiza, F.M.; Duarte, Y.B.; Mendez-Sanchez, S.C.; Bohórquez, A.R.R. Synthesis and in vitro evaluation of substituted tetrahydroquinoline-isoxazole hybrids as anticancer agents. *Med. Chem. Res.* 2019, 28, 1182–1196. [CrossRef]
- 4. Wang, H.; Ma, Y.; Lin, Y.; Liu, J.; Chen, R.; Xu, B.; Liang, Y. An Isoxazole derivative SHU00238 suppresses colorectal cancer growth through miRNAs regulation. *Molecules* **2019**, *24*, 2335. [CrossRef] [PubMed]
- 5. Xue, X.; Zhang, Y.; Wang, C.; Zhang, M.; Xiang, Q.; Wang, J.; Wang, A.; Li, C.; Zhang, C.; Zou, L.; et al. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. *Eur. J. Med. Chem.* **2018**, *152*, 542–559. [CrossRef] [PubMed]
- 6. Santos, M.M.M.; Faria, N.; Iley, J.; Coles, S.J.; Hursthouse, M.B.; Martins, M.L.; Moreira, R. Reaction of naphthoquinones with substituted nitromethanes. Facile synthesis and antifungal activity of naphtho[2,3-*d*]isoxazole-4,9-diones. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 193–195. [CrossRef] [PubMed]
- Yu, L.F.; Tückmantel, W.; Eaton, J.B.; Caldarone, B.; Fedolak, A.; Hanania, T.; Brunner, D.; Lukas, R.J.; Kozikowski, A.P. Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity. *J. Med. Chem.* 2012, *55*, 812–823. [CrossRef] [PubMed]
- Padmaja, A.; Rajasekhar, C.; Muralikrishna, A.; Padmavathi, V. Synthesis and antioxidant activity of oxazolyl/thiazolylsulfonylmethyl pyrazoles and isoxazoles. *Eur. J. Med. Chem.* 2011, 46, 5034–5038. [CrossRef] [PubMed]
- 9. Moraski, G.C.; Chang, M.; Villegas-Estrada, A.; Franzblau, S.G.; Möllmann, U.; Miller, M.J. Structure–activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters. *Eur. J. Med. Chem.* **2010**, *45*, 1703–1716. [CrossRef] [PubMed]
- 10. Zhou, Y.; Chen, Y.; Miao, W.; Qu, J. Synthesis, structures, and herbicidal activity of isoxazole derivatives. *J. Heterocycl. Chem.* **2010**, *47*, 1310–1316. [CrossRef]
- 11. Upadhyay, A.; Gopal, M.; Srivastava, C.; Pandey, N.D. Isoxazole derivatives as a potential insecticide for managing Callosobruchus chinensis. *J. Pestic. Sci.* **2010**, *35*, 464–469. [CrossRef]
- Alves, A.J.S.; Lopes, S.M.M.; Henriques, M.S.C.; Paixão, J.A.; Pinho e Melo, T.M.V.D. Hetero-Diels–Alder and ring-opening reactions of furans applied to the synthesis of functionalized heterocycles. *Eur. J. Org. Chem.* 2017, 27, 4011–4025. [CrossRef]
- 13. Voskienė, A.; Mickevičius, V. Cyclization of chalcones to isoxazole and pyrazole derivatives. *Chem. Heterocycl. Compd.* **2009**, *45*, 1485–1488.
- 14. For application of some related systems through the functionalization of enone fragment, see: Trushkov, I.V.; Uchuskin, M.U.; Abaev, V.T.; Serdyuk, O.V. Indolylvinyl ketones: Building blocks for the synthesis of natural products and bioactive compounds. *Synthesis* **2019**, *51*, 787–815.
- 15. Merino, P.; Tejero, T.; Delso, J.I.; Matute, R. Furan oxidations in organic synthesis: Recent advances and applications. *Curr. Org. Chem.* **2007**, *11*, 1076–1091. [CrossRef]
- 16. Makarov, A.S.; Uchuskin, I.V.; Trushkov, I.V. Furan oxidation reactions in the total synthesis of natural products. *Synthesis* **2018**, *50*, 3059–3086.
- 17. Dugave, C.; Demange, L. Cis–Trans isomerization of organic molecules and biomolecules: implications and applications. *Chem. Rev.* **2003**, *103*, 2475–2532. [CrossRef] [PubMed]
- 18. Sawengngen, N.; Chalikidi, P.N.; Araby, S.; Hampel, F.; Gmeiner, P.; Serdyuk, O.V. Synthesis of pyrazolylvinyl ketones from furan derivatives. *Org. Biomol. Chem.* **2019**, *17*, 4850–4855. [CrossRef] [PubMed]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).